2026-07-21T08:01:28Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/254862025-12-18T12:55:45Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Laniece Delaunay, Charlotte author Melo, Aryse author Maurel, Marine author Mazagatos, Clara author Goerlitz, Luise author O'Donnell, Joan author Oroszi, Beatrix author Sève, Noémie author Rodrigues, Ana Paula author Martínez-Baz, Iván author Meijer, Adam author Mlinarić, Ivan author Latorre-Margalef, Neus author Lazar, Mihaela author Pérez-Gimeno, Gloria author Dürrwald, Ralf author Bennett, Charlene author Túri, Gergő author Rameix-Welti, Marie-Anne author Guiomar, Raquel author Castilla, Jesús author Hooiveld, Mariëtte author Kurečić Filipović, Sanja author Samuelsson Hagey, Tove author Dijkstra, Frederika author Borges, Vítor author Ramos Marín, Violeta author Bacci, Sabrina author Kaczmarek, Marlena author Kissling, Esther author European Primary Care Vaccine Effectiveness Group author 2024-07-25 In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case-control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26-53 %) overall, 48 % (95 % CI: 31-61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3-49 %) at 6-14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies. Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024. Vaccine. 2024 Jul 25;42(19):3931-3937. 10.1016/j.vaccine.2024.05.067 1873-2518 0264-410X Vaccine 38839521 https://hdl.handle.net/20.500.12105/25486 COVID-19 Europe Multicentre study SARS-CoV-2 Test-negative design Vaccine effectiveness Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024